|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 492.80 DKK | -4.16% |
|
-2.99% | -31.13% |
| 12-12 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 12-11 | Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration | RE |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology | 353M | 293M | 104M | 343M | 62.69M | |||||
Total Assets | 1.76B | 2.07B | 1.54B | 1.98B | 9.51B | |||||
Interest Expense | -2.9M | -4.09M | -57.79M | -25.83M | -34.05M | |||||
Income Tax Expense | 7.08M | -8.79M | -6.43M | -5.13M | -4.62M | |||||
CAPEX | -25.04M | -22.13M | -11.71M | -11.24M | -10.05M | |||||
EBT | -840M | -1.03B | -972M | -709M | -1.08B | |||||
Gross Profit | 263M | 174M | 104M | 324M | 54.82M | |||||
D&A | 29.96M | 40.25M | 102M | 20.12M | 23.12M | |||||
Operating Income | -792M | -1.05B | -837M | -572M | -1.27B | |||||
Net Income | -847M | -1.02B | -1.2B | -704M | -1.08B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Denmark | - | - | 35M | 44.18M | 62.28M | |||||
Total Assets | 184M | 185M | 144M | 137M | 125M | |||||
United States | 204M | 240M | 69M | 4.09M | 406K | |||||
Total Assets | 71.1M | 107M | 21.7M | 13.03M | - | |||||
Germany | 149M | 53M | - | 295M | - | |||||
Foreign | - | - | - | - | - |
- Stock Market
- Equities
- ZEAL Stock
- Financials Zealand Pharma A/S
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition